Free Trial

Pluri (PLUR) Competitors

Pluri logo
$4.95 -0.46 (-8.50%)
Closing price 03:34 PM Eastern
Extended Trading
$4.66 -0.29 (-5.86%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLUR vs. CYBN, VYGR, IMAB, ACOG, LFVN, DERM, IPHA, ENTA, SPRO, and NVCT

Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cybin (CYBN), Voyager Therapeutics (VYGR), I-Mab (IMAB), Alpha Cognition (ACOG), Lifevantage (LFVN), Journey Medical (DERM), Innate Pharma (IPHA), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

Pluri vs. Its Competitors

Pluri (NASDAQ:PLUR) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Cybin had 2 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Cybin and 0 mentions for Pluri. Pluri's average media sentiment score of 1.87 beat Cybin's score of 0.69 indicating that Pluri is being referred to more favorably in the media.

Company Overall Sentiment
Pluri Very Positive
Cybin Positive

16.6% of Pluri shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 25.9% of Pluri shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cybin has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Cybin's return on equity of -37.58% beat Pluri's return on equity.

Company Net Margins Return on Equity Return on Assets
Pluri-2,563.29% -4,191.91% -85.40%
Cybin N/A -37.58%-36.59%

Pluri has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$330K118.05-$20.89M-$5.53-0.90
CybinN/AN/A-$57.88M-$3.88-2.14

Pluri currently has a consensus price target of $12.00, indicating a potential upside of 142.42%. Cybin has a consensus price target of $85.00, indicating a potential upside of 921.63%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Pluri.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluri
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cybin
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Pluri has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Summary

Cybin beats Pluri on 10 of the 15 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLUR vs. The Competition

MetricPluriMED IndustryMedical SectorNASDAQ Exchange
Market Cap$42.58M$2.91B$5.52B$9.41B
Dividend YieldN/A2.45%3.80%4.04%
P/E RatioN/A19.8828.0419.84
Price / Sales118.05305.11429.5399.59
Price / CashN/A43.1635.8457.94
Price / Book4.957.678.125.65
Net Income-$20.89M-$55.28M$3.25B$258.00M
7 Day Performance-6.78%2.50%0.97%2.09%
1 Month Performance14.85%11.70%7.36%11.13%
1 Year Performance-10.81%4.89%31.31%18.40%

Pluri Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLUR
Pluri
3.5764 of 5 stars
$4.95
-8.5%
$12.00
+142.4%
-5.6%$42.58M$330K-0.90150Positive News
Gap Down
CYBN
Cybin
2.8641 of 5 stars
$7.70
-2.2%
$86.00
+1,017.5%
N/A$176.13MN/A-1.7550News Coverage
VYGR
Voyager Therapeutics
4.0186 of 5 stars
$3.15
+3.6%
$13.39
+325.1%
-63.1%$173.82M$80M-2.15100News Coverage
IMAB
I-Mab
2.871 of 5 stars
$2.13
+1.7%
$6.00
+182.4%
+42.1%$173.53M$3.89M0.00380News Coverage
ACOG
Alpha Cognition
1.7412 of 5 stars
$10.75
-4.4%
$20.00
+86.0%
N/A$172.22MN/A-8.96N/A
LFVN
Lifevantage
4.2541 of 5 stars
$13.43
-1.2%
$30.50
+127.1%
+107.6%$169.02M$200.16M19.46260News Coverage
DERM
Journey Medical
2.265 of 5 stars
$7.23
+1.8%
$9.50
+31.4%
+27.4%$165.55M$56.13M-18.2290
IPHA
Innate Pharma
2.3347 of 5 stars
$1.79
-1.6%
$11.00
+514.5%
-18.0%$165.00M$21.77M0.00220News Coverage
Gap Up
ENTA
Enanta Pharmaceuticals
3.7724 of 5 stars
$7.77
-1.5%
$18.00
+131.7%
-54.3%$164.26M$67.64M-1.69160Positive News
SPRO
Spero Therapeutics
3.9397 of 5 stars
$2.94
+1.2%
$5.00
+70.4%
+67.6%$164.10M$47.98M-2.29150Positive News
NVCT
Nuvectis Pharma
3.2049 of 5 stars
$7.82
-0.4%
$17.00
+117.5%
+17.4%$163.36MN/A-6.928Positive News

Related Companies and Tools


This page (NASDAQ:PLUR) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners